On this episode, you’ll hear from Kenneth Davis, M.D., president and CEO of Mount Sinai Health System in New York, a system that was on the front lines of the first wave of COVID-19. He is a neurobiologist and a pioneering researcher in the field of brain disease, notably Alzheimer’s disease.

Dr. Davis discusses lessons learned during the COVID-19 pandemic and how to better prepare for further surges or another virus. In our conversation he says, “We just need to be ready,” emphasizing the necessity for the U.S. to be a leader in responding to a future global pandemic, including on diagnostic testing and vaccines.

Responding to a public health emergency of this scale reveals the benefits of working and collaborating in a large, integrated health system. Dr. Davis reflects on his system’s experience and on a range of related topics including health care inequities, social determinants of health, and using a population health model to provide care and keep people well.

Look for more of my conversations on trending topics with health care leaders from around the country, released as part of the Chair File.

Rod Hochman, M.D.
AHA Chair

 

 

Related News Articles

Headline
With June 9-13 being Community Health Improvement Week, three experts from HonorHealth discuss how the health care network is addressing community needs beyond…
Headline
A new AHA video highlights how Corewell Health is transforming youth behavioral health care access in rural Michigan through school-based clinics and…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Chairperson's File
Public
We are all closely watching changing tariff policy as it raises serious considerations for the medical products, devices and pharmaceuticals supply chain. Our…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
The Food and Drug Administration May 16 announced it cleared the first blood test to diagnose Alzheimer’s disease. The test, created by Fujirebio Diagnostics,…